|Prasugrel (Effient) for acute coronary syndromes in people undergoing percutaneous coronary intervention
||Prasugrel is an alternative to clopidogrel for acute coronary syndrome managed by percutaneous coronary intervention in combination with aspirin.
|Immediate-release pramipexole (Sifrol) and extended-release pramipexole (Sifrol ER) for Parkinsons disease
||Information on use of immediate-release pramipexole (Sifrol) and extended-release pramipexole (Sifrol ER) for Parkinson's disease.
|Olanzapine long-acting injection (Zyprexa Relprevv) for schizophrenia
||Information about use of olanzapine depot injection (Zyprexa Relprevv) for schizophrenia
|Brief item: varenicline safety update: serious neuropsychiatric and dermatological adverse events
||Safety update regarding serious neuropsychiatric and dermatological adverse events associated with varenicline (Champix)
|Brief item: etoricoxib (Arcoxia): be aware of hypertension risk
||Information about hypertension risk associated with use of the COX-2 selective NSAID etoricoxib (Arcoxia)
|Brief item: new pneumococcal polysaccharide conjugate vaccine (Synflorix) added to the national immunisation schedule
||Information about use of the 10-valent pneumococcal polysaccharide conjugate vaccine, Synflorix, for Streptococcus pneumoniae
|Brief item: montelukast (Singulair) PBS listed for exercise-induced asthma in children aged 6-14 years
||Information about use of montelukast (Singulair) for exercise-induced asthma in children aged 6–14 years
|Brief item: Authority listing for ciprofloxacin ear drops extended
||Extension of authority listing for ciprofloxacin ear drops (Ciloxan), 1 November 2009
|NPS RADAR December 2009
||NPS RADAR articles provide timely, independent, evidence-based assessment of new drugs, new PBS listings and research for health professionals.